CVRx, Inc.
NASDAQ:CVRXMedical - Devices
+$0.11 today
- Market cap
- $69.79M
- Beta
- 0.77
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$2.00
Volume 0.37M
Average 0.30M
CVRX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
CVRx, Inc.NASDAQ: CVRX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $3.08M rose 22.5% year over year, ahead of the +10.5% change in trailing-twelve-month research & development. Sequentially, it rose 2.8% from the prior quarter. Over 3 fiscal years it compounded at +3.8% a year.
Context
- Research & development amounted to 19.7% of revenue in FY2025, down 2.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +22.5% holds above the trailing-twelve-month pace of +10.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 11.13M USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- +10.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.13M | +0.0% |
| FY2024 | 2024-12-31 | 11.13M | -4.3% |
| FY2023 | 2023-12-31 | 11.63M | +16.9% |
| FY2022 | 2022-12-31 | 9.95M | +32.7% |
| FY2021 | 2021-12-31 | 7.5M | — |
Research & Development vs competitors
How CVRX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +10.5% is the 3rd highest of 10, against a peer median of -4.7%.
- Research & development amounts to 19.8% of revenue for CVRX, versus a peer median of 24.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $65.65M USD | +7.6% | +0.8% | 29.5% | |
| LTM Mar 2026 | €44.34M EUR | +12.6% | -7.1% | 329.9% | |
| LTM Mar 2026 | $33.21M USD | -3.4% | +10.2% | 22.9% | |
| LTM Mar 2026 | $32.9M USD | -13.4% | -7.3% | 80.8% | |
| LTM Dec 2025 | $19.24M USD | -4.7% | -10.1% | 147.7% | |
| LTM Mar 2026 | $13.97M USD | -23.1% | -7.7% | 24.2% | |
| LTM Mar 2026 | $12.72M USD | -28.5% | -13.9% | 16.0% | |
| LTM Mar 2026 | $11.7M USD | +10.5% | +3.8% | 19.8% | |
| LTM Mar 2026 | $2.8M USD | -10.1% | +3.8% | 1.0% | |
| LTM Mar 2026 | $1.81M USD | +151.4% | +33.6% | 4.1% | |
| Peer median (excluding CVRX) | — | -4.7% | -7.1% | 24.2% | |
Competitors are the stored peer set for CVRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.04M | 22.47M | 39.3M | 51.29M | 56.65M |
| Cost of Revenue | 3.64M | 5M | 6.26M | 8.33M | 8.31M |
| Gross Profit | 9.4M | 17.47M | 33.04M | 42.96M | 48.34M |
| Gross Margin | 72.1% | 77.8% | 84.1% | 83.8% | 85.3% |
| Research & Development | 7.5M | 9.95M | 11.63M | 11.13M | 11.13M |
| Selling, General & Admin | 27.86M | 50.05M | 64.51M | 91.32M | 88.47M |
| Operating Expenses | 35.36M | 60M | 76.14M | 102.45M | 99.61M |
| Depreciation & Amortization | 168K | 412K | 522K | 619K | 756K |
| EBITDA | (40.6M) | (40.74M) | (38.73M) | (54.89M) | (46.74M) |
| EBITDA Margin | -311.4% | -181.3% | -98.6% | -107.0% | -82.5% |
| Operating Income | (25.97M) | (42.53M) | (43.1M) | (59.49M) | (51.27M) |
| Operating Margin | -199.2% | -189.3% | -109.7% | -116.0% | -90.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2.22M | 165K | 1.8M | 4.4M | 5.83M |
| Other Income / Expenses | (17.02M) | 1.21M | 2.05M | (420K) | (2.06M) |
| Income Before Tax | (42.99M) | (41.32M) | (41.05M) | (59.91M) | (53.32M) |
| Pre-Tax Margin | -329.8% | -183.9% | -104.5% | -116.8% | -94.1% |
| Income Tax Expense | 91K | 109K | 147K | 55K | (18K) |
| Net Income | (43.08M) | (41.43M) | (41.2M) | (59.97M) | (53.31M) |
| Net Margin | -330.5% | -184.4% | -104.8% | -116.9% | -94.1% |
| EPS (Basic) | (2.11) | (2.02) | (1.99) | (2.65) | (2.04) |
| EPS (Diluted) | (2.11) | (2.02) | (1.99) | (2.65) | (2.04) |
| Weighted Avg Shares | 20.72M | 20.51M | 20.7M | 22.6M | 26.08M |
| Weighted Avg Shares (Diluted) | 20.72M | 20.53M | 20.75M | 22.6M | 26.08M |
CVRx, Inc.
NASDAQ:CVRX
Intrinsic Alpha fair value
Locked
Current Price
$2.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.